Why the study?
Available treatments for endothelial dysfunction and vasoocclusive remodeling slow disease progression but do not prevent deterioration, highlighting the need for therapies that reverse vascular degeneration.
Answers are grounded in this paper and cite their sources.
PPARγ agonists like pioglitazone may offer a novel regenerative therapeutic strategy for pulmonary arterial hypertension by enhancing DNA damage response and repair.
Endothelial dysfunction with subsequent degeneration and vasoocclusive remodeling is the hallmark of many cardiovascular disorders including pulmonary vascular disease (PVD). To date, the available treatments slows disease progression but does not prevent deterioration. Reversing such pathologies would spare many patients risky surgeries and long waiting lists for a possible organ donor. Peroxisome proliferator-activated receptor agonists were first introduced as sole insulin sensitizers, however, there is increasing body of evidence that they have different actions on DNA which might help reverse vascular degeneration. This effect appears to be mainly achieved through enhancement of DNA damage responses (DDR). The aforementioned effect could offer new insights about repurposing drugs for achieving organ or tissue regeneration, an understudied field named drug-induced regenerative medicine.
No takes yet. Share an insight, caveat, or question.
Afdal et al. (2020) conducted a review in Pulmonary arterial hypertension. PPARγ agonists (pioglitazone) was evaluated.
Synapse has enriched 10 related papers. Consider them for comparative context: